Coronary Artery Disease, Microvascular Dysfunction
Conditions
Keywords
microvascular disease, coronary artery disease, Coronary artery disease, with or without microvascular dysfuntion
Brief summary
Primary goal of the registry is to collect prospective data on patients undergoing coronary angiography in Mainz. Following amendment of the procol, this study will also include patients who received an Aborb bioresorbable scaffold for the therapy of de novo stenoses.
Detailed description
Patients included in the registry will be contacted by telephone at 3,6,9, 12 months and 2, 5, 10 years after the procedure. In case coronary slow flow is shown at the index procedure, 39ml of blood will be drawn for further studies. According to the regulations of the Province Rheinland-Pfalz, national law, and with the approval of the Ethic commission of the Landesärztekammer Rheinland Pfalz, patients (n=1000) will also be retrospectively entered in the database in an anonymous way. For these patients, no specific study procedure is foreseen and the MICAT database will be only used as a platform (database of anonymous data collected during routine clinical practice).
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* clinical indication to coronary angiography
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse cardiovascular events | baseline to 10 years | Incidence of major adverse events (death, death of cardiac cause, TLR - target lesion revascularization, MI) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Individual endpoints | baseline to 10 years | Each individual endpoint of the MACE previously described |
| Other cardiovascular endpoints | baseline to 10 years | TVR - target vessel revascularization, re-hospitalization, change in medications. |
Countries
Germany